Therapeutic and Supportive Effects of Cannabinoids in Patients with Brain Tumors (CBD Oil and Cannabis)

被引:0
作者
J. Eduardo Rodriguez-Almaraz
Nicholas Butowski
机构
[1] University of California San Francisco,Neuro Surgery Department Division of Neuro
[2] University of California San Francisco,Oncology
[3] University of California San Francisco,Deparment of Epidemiology and Biostatistics
来源
Current Treatment Options in Oncology | 2023年 / 24卷
关键词
Cannabinoids; Gliomas; Palliative care; Antitumor therapy; Symptom management;
D O I
暂无
中图分类号
学科分类号
摘要
The potential medicinal properties of Cannabis continue to garner attention, especially in the brain tumor domain. This attention is centered on quality of life and symptom management; however, it is amplified by a significant lack of therapeutic choices for this specific patient population. While the literature on this matter is young, published and anecdotal evidence imply that cannabis could be useful in treating chemotherapy-induced nausea and vomiting, stimulating appetite, reducing pain, and managing seizures. It may also decrease inflammation and cancer cell proliferation and survival, resulting in a benefit in overall patient survival. Current literature poses the challenge that it does not provide standardized guidance on dosing for the above potential indications and cannabis use is dominated by recreational purposes. Furthermore, integrated and longitudinal studies are needed but these are a challenge due to arcane laws surrounding the legality of such substances. The increasing need for evidence-based arguments about potential harms and benefits of cannabis, not only in cancer patients but for other medical use and recreational purposes, is desperately needed.
引用
收藏
页码:30 / 44
页数:14
相关论文
共 54 条
  • [1] Concannon RM(2015)Differential upregulation of the cannabinoid CB2 receptor in neurotoxic and inflammation-driven rat models of Parkinson’s disease Exp Neurol. Academic Press 269 133-141
  • [2] Okine BN(2007)Distinctive pattern of cannabinoid receptor type II (CB2) expression in adult and pediatric brain tumors Brain Res. 1137 161-169
  • [3] Finn DP(2017)Pharmacogenetics of cannabinoids Eur J Drug Metab Pharmacokinet 43 1-12
  • [4] Dowd E(2001)Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review BMJ. 323 16-21
  • [5] Ellert-Miklaszewska A(2011)Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial Annal Oncol Elsevier 22 2086-2093
  • [6] Grajkowska W(2013)Compound K is able to ameliorate the impaired cognitive function and hippocampal neurogenesis following chemotherapy treatment Biochem Biophys Res Commun. Academic Press 436 104-109
  • [7] Gabrusiewicz K(2018)A Call for a Neuroscience Approach to Cancer-Related Cognitive Impairment Trends Neurosci. Elsevier Current Trends 41 493-496
  • [8] Kaminska B(2001)Ceramide: a new second messenger of cannabinoid action Trends Pharmacol Sci. 22 19-22
  • [9] Konarska L(2004)Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas Cancer Res. 64 5617-5623
  • [10] Hryhorowicz S(2020)A systematic review and meta-analysis examining the effects of cannabis and its derivatives in adults with malignant CNS tumors Neurooncol Pract. Oxford University Press 7 376-383